Announcements Trials
Browse Landscape

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 21Observational 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1SCLC, Extensive Stage 1Melanoma 1Lung Neoplasms 1Liver Diseases 1Esophageal Neoplasms 1Breast Neoplasms 1Advanced Colorectal Carcinoma 1

Interventions

Sorafenib 20lenvatinib 18Hepatectomy 17Blood Specimen Collection 12Immune Checkpoint Inhibitors 11Liver Transplantation 9atezolizumab 8Surgical Procedures, Operative 7Radiofrequency Ablation 7Observation 7Bevacizumab 6regorafenib 5gadolinium ethoxybenzyl DTPA 5sintilimab 4donafenib 4camrelizumab 4Radiotherapy 4Magnetic Resonance Spectroscopy 4tislelizumab 3spartalizumab 3Polymerase Chain Reaction 3Neoadjuvant Therapy 3Mass Spectrometry 3Immunohistochemistry 3Doxorubicin 3Angiogenesis Inhibitors 3toripalimab 2pembrolizumab 2entecavir 2apatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Observational × Carcinoma, Hepatocellular × toripalimab × Clear all
NCT06333561 2025-02-06

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Sun Yat-sen University

Recruiting
300 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT04627012 2024-03-06

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

Sun Yat-sen University

Completed
600 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Liver Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡